Pain Management News

A novel digital therapeutic for migraine prevention met its primary endpoint of reducing the number of monthly migraine days, according to results from a phase 3 clinical trial.

In patients with difficult-to-treat migraine, IV infusion of a novel monoclonal antibody provided superior migraine frequency relief compared with placebo in as early as 4 weeks, data show.

Prodromal treatment with 100 mg ubrogepant was associated with greater functionality, fewer activity limitations and a high degree of satisfaction at 24 hours in patients with migraine, according to research published in Neurology.

According to results of a six-nation global survey, individuals with migraine experienced a high level of symptom burden and severity, negatively affecting their quality of life including mood.

Deep brain stimulation (DBS) therapy has been a safe and effective treatment option for Parkinson’s disease for more than 30 years, but another surgical option for the therapy has emerged.

A Maryland-based neurotechnology company has secured a U.S. patent for its novel prosthetic translucent, cranial implant intended for use during neurosurgical procedures.

The FDA has granted 510(k) clearance to a plant-based, hemostatic gel to treat moderate to severe bleeding, according to the manufacturer.

The FDA has granted rare pediatric disease designation to an investigational oligonucleotide for the treatment of boys with Duchenne muscular dystrophy who are amenable to exon 53 skipping, according to the manufacturer.

The Healio news staff received an APEX award in the category of Writing/Topics for work on the potential role of psychedelics and alternative therapies for mental health issues and other medical conditions.

In young male American football players, concussion symptoms and severity were higher for those who sustained the injury on natural grass compared with artificial turf, according to new research in the Clinical Journal of Sports Medicine.